A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Adenocarcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms REPROVe
- Sponsors DelMar Pharmaceuticals
- 16 Oct 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Feb 2019 Planned End Date changed from 1 Jun 2020 to 1 Sep 2022.
- 19 Feb 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2022.